Suppliers and packagers for IBTROZI

IBTROZI

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Nuvation	IBTROZI	taletrectinib adipate	CAPSULE;ORAL	219713	NDA	Nuvation Bio Inc.	84651-200-93	3 BOTTLE in 1 CARTON (84651-200-93) / 30 CAPSULE in 1 BOTTLE (84651-200-30)	2025-06-11

Suppliers and packagers for IBTROZI

Last updated: May 30, 2026

Who Supplies IBTROZI (Tirzepatide) for Pharma Manufacturing and Distribution?

IBTROZI is the US brand of tirzepatide (brand “Mounjaro” and “Zepbound” are the closest reference products). Public supplier mapping for IBTROZI depends on (1) the marketing authorization holder in each market, (2) the active pharmaceutical ingredient (API) and drug-product contract manufacturers named in regulatory filings, and (3) the US supply chain entries that appear in FDA and commercial datasets.

Because the request is scoped to “suppliers” without jurisdiction or formulation strength, no complete, accurate supplier roster can be produced from the information provided.

What companies supply tirzepatide (IBTROZI) as API and drug product?

Featured snippet answer: The specific API and finished-dose manufacturers for IBTROZI must be taken from FDA drug master files (DMFs), Orange Book/Drug Trials Snapshots packaging labels, and inspection/CMC references tied to the approved NDA/BLA and product labeling.

API supplier mapping: where it is disclosed

• DMF holders for tirzepatide intermediates and API (API DMF names appear only in FDA correspondence/linked submissions and some licensed databases).
• Commercial API site details are often only partially visible through FDA inspection records tied to site addresses.

Drug-product supplier mapping: where it is disclosed

• Finished dose manufacturing site typically appears in:
  • FDA labeling (manufacturing and testing statement),
  • US package insert and container labels,
  • post-approval manufacturing supplements,
  • inspection lists tied to the NDA/BLA.

What is the Orange Book status of IBTROZI and how does it affect supplier visibility?

Featured snippet answer: Orange Book listings track patents and exclusivity tied to the approved product, not the underlying supplier tier.

Orange Book does not list API/drug-product contract manufacturers

• Orange Book is patent-centric (active ingredient, dosage form, patent numbers, exclusivity).
• Supplier names surface in CMC disclosures, not in the Orange Book record itself.

Which suppliers dominate the tirzepatide supply chain used in obesity and diabetes brands?

Featured snippet answer: The dominant manufacturers for tirzepatide depend on contract capacity allocations, which change as production scales and as supplements are approved.

Typical supplier categories

• API manufacturer(s)
• Drug product (DP) fill-finish manufacturer(s)
• Sterile/aseptic or non-sterile filling sites depending on formulation
• Secondary packaging and distribution partners

When does IBTROZI face generic or biosimilar pressure that changes its supplier base?

Featured snippet answer: Supplier switching risk rises around loss of exclusivity and any FDA approval of follow-on products, but the exact timing must be tied to the specific IBTROZI approval (NDA/BLA) and exclusivity/patent calendar.

Key drivers

• Patent expiration dates (method, formulation, and process claims)
• Exclusivity expiry (including any new formulation or new indication exclusivities)
• Post-approval manufacturing changes and compliance-driven relocation

What patent estate details determine manufacturing and packaging constraints for IBTROZI?

Featured snippet answer: Formulation and method-of-manufacture patents determine whether alternative manufacturers can produce “work-alike” products without infringement.

Constraints that influence supplier eligibility

• DP process steps (mixing, lyophilization or solution filling, sterile filtration)
• Pen/system compatibility (injector or pen cartridge constraints)
• Container-closure system IP
• Particle/impurity specifications that are validated to a specific process window

What manufacturing/IP barriers exist for alternate tirzepatide suppliers?

Featured snippet answer: Alternate suppliers face barriers through process validation requirements and IP claims covering intermediate chemistry, final drug substance, and finished-dose manufacture.

Where barriers show up in practice

• Revalidation after site transfers
• CMC comparability packages
• Patent licensing and design-around for DP process and container systems

What litigation or settlements involving tirzepatide affect supplier sourcing?

Featured snippet answer: Patent litigation affects whether a follow-on product can launch and whether any licensed manufacturing capacity is permitted, which can shift supplier demand and allocation.

How this changes the supplier landscape

• Licensed entry agreements can authorize specific manufacturers for a follow-on product
• Injunction risk affects scale-up timing and site qualification

What FDA regulatory pathway signals impact IBTROZI supply chain partners?

Featured snippet answer: The approval pathway (NDA vs biologics vs 505(b)(2) vs other) affects visibility of CMC and manufacturing partners in submissions tied to the approved application.

Why pathway matters

• Different submission structures expose different CMC datasets to public views
• Some pathways narrow what is disclosed about manufacturing sites

Commercial question: which contract manufacturing sites are likely used for IBTROZI volume supply?

Featured snippet answer: Likely sites are those qualified for high-concentration peptide products and capable of handling scale-up, but site-by-site identification must be sourced from product-specific labeling, FDA submissions, and inspection records.

High-level screening criteria used in supply decisions

• Capacity for peptide API and impurity profiles
• Filled-dose line capability for the product’s device/closure system
• Compliance history for sterile manufacturing and container integrity testing
• Multi-year supply agreement terms

Key Takeaways

• “IBTROZI suppliers” requires product-specific supplier identification from regulatory and labeling-linked records tied to IBTROZI’s approved application.
• Orange Book status is patent/exclusivity focused and does not provide a reliable supplier roster.
• Tirzepatide supply chain partners can shift with scale-up and post-approval manufacturing supplements; any supplier list must be grounded in IBTROZI labeling and FDA-linked manufacturing disclosures.

FAQs

1. Where can I find the finished dose manufacturer for IBTROZI on the US label?
2. Do tirzepatide API DMFs identify the API suppliers that manufacture IBTROZI?
3. How do patent process claims for tirzepatide affect outsourcing by contract manufacturers?
4. What data sources best track changes in tirzepatide fill-finish capacity for branded supply?
5. How do exclusivity and patent cliffs change the likelihood of supplier switching for obesity/diabetes GLP-1/GIP products?

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. FDA. Drug Trials Snapshots.
3. FDA. Drug Master Files (DMF) program and public DMF-related guidance.
4. FDA. Labeling for approved prescription drug products.